Monthly Archives: January 2016

Dr. Adam Fleisher (fall 2007 Grad) was recently promoted to Medical Director of Global Clinical Trials for Eli Lilly Alzheimer’s Disease team

Dr. Adam Fleisher (fall 2007 Grad) was recently promoted to Medical Director of Global Clinical Trials for Eli Lilly Alzheimer’s Disease team

Fall 2007 Grad Dr. Adam Fleisher was recently promoted to serve as Medical Director of Phase III Global Trials for Eli Lilly Alzheimer’s Disease team.  He was previously Director of Global Medical Affairs for Eli Lilly. From 2008-2014 he was the Director of Imaging at Banner Alzheimer’s Institute where he managed the imaging center and cyclotron facility, the computational imaging laboratory, and functioned as a site investigator for dementia clinical trials. He continues to care for patients at the Banner Alzheimer’s Institute memory disorder clinic, and holds an academic appointment as an Associate Professor, Department of Neurosciences, at the University of California, San Diego, where he served as the Medical Director of the Alzheimer’s Disease Cooperative Study from 2003-2013. He received his medical degree from the University of Rochester School of Medicine, New York, and obtained his general neurology training at Johns Hopkins Hospital in Baltimore, Maryland. He then completed a clinical and research dementia fellowship at UC San Diego, as well as the Master of Advanced Studies degree in Clinical Research. He has published in both MRI and PET imaging (FDG and Amyloid), as well as clinical trials in Alzheimer’s disease, with a research focus on influences of aging and genetic risk factors for Alzheimer’s disease and predictive bio marker development in cognitively normal elderly adults.

“My MAS degree has played a key role in my career growth.” –  Dr. Adam Fleisher

Dr. Linda Awdishu (Spring 2007 Grad), Won a Campus Wide Teaching Award in 2015 and Won a National Pharmacy Award

Dr. Linda Awdishu (Spring 2007 Grad), Won a Campus Wide Teaching Award in 2015 and Won a National Pharmacy Award

Linda Awdishu, PharmD, MAS, an Associate Clinical Professor of Pharmacy at UC San Diego Skaggs School of Pharmacy and spring 2007 MAS grad in Clinical Research, was awarded  the Barbara and Paul Saltman Distinguished Teaching award in June 2015. The Distinguished Teaching Award was created because UC San Diego faculty recognize the important role excellent teaching plays at the University. This Award is a tangible expression of UC San Diego’s commitment to excellence in teaching and to ensuring that this commitment is maintained. The Committee on Distinguished Teaching seeks to select those who exhibit creativity, innovative teaching methods, the ability to motivate students to actively seek out knowledge, and an extraordinary level of teaching commitment.

In addition, Linda and her team won a 2014 national pharmacy award – ASHP Foundation National Award for Excellence in Medication Safety:

UC San Diego Health System
San Diego, CA
EHR “Best Practice Alerts” Improve Medication Safety in Kidney Patients
Patients with acute kidney injury and chronic kidney disease are at risk for frequent adverse medical events due to improper medication dosing. An interprofessional pharmacist-led team comprised of specialists in pharmacy and medical informatics from the health system and the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences sought to design and implement a computerized decision support tool to improve the rate of appropriate medication prescriptions in patients with kidney impairment. The tool was designed to evaluate new medication orders as well as existing medication orders in patients with declining kidney function.  

The UC San Diego team used the “Best Practice Alert” function in their electronic health record software to create the decision support tool. Twenty medications that require dosage adjustment for patients with kidney dysfunction were identified. Physicians at UC San Diego were randomized to receive either standard of care (pharmacist review after order signing) or alerts in addition to standard of care. A total of 4,113 opportunities for potential drug dosage adjustment or discontinuation occurred in 1,649 unique patients. The primary outcome—drug discontinuation or appropriate dosage adjustment—occurred in 17 percent vs. 5.6 percent of opportunities in the intervention and control arm, respectively (OR 2.66 [95%CI 2.00-3.53], p<0.0001). The effect of the intervention was sustained over time.